Maternal perspectives on the use of probiotics in infants: a cross-sectional survey
© Bridgman et al.; licensee BioMed Central Ltd. 2014
Received: 16 July 2014
Accepted: 27 August 2014
Published: 29 September 2014
Probiotic products that may modify the intestinal microbiota are becoming increasingly available and known to consumers due to their potential to prevent or treat many pediatric health conditions. As scientific knowledge of the health benefits of probiotics increases, it is important to identify factors that may prevent their successful integration into patient care as well as to ensure effective translation of research findings. The aim of this study was to describe maternal perspectives on probiotics and their use in infants.
Mothers with a child aged two years or younger enrolled in the Alberta Pregnancy Outcomes and Nutrition (APrON) study were invited by email to complete a 29 item self-administered web-based questionnaire.
A total of 413 mothers of the 1327 contacted completed the questionnaire. The majority (99.3%) of respondents had heard of probiotics and were aware that they contained live bacteria (87.0%); 89.3% had used a product containing probiotics themselves but only 50.8% had given one to their infant. Most mothers indicated they believed that probiotics were beneficial (73.1%) and none thought they were harmful. Over a third of mothers did not feel informed enough to make a decision on whether probiotics were safe to use in infants (36.6%).
The study demonstrates that awareness and understanding of probiotics is high among mothers in Alberta, Canada. However, there is still uncertainty regarding the benefit of probiotics as well as safety in infants which could be important factors determining therapeutic use in the future. Further studies that demonstrate beneficial effects and safety of probiotics in healthy infants as well as targeted knowledge translation should help to address these potential concerns.
KeywordsProbiotics Infant Mother Nutrition Natural health products Cross-sectional survey
Due to the association between the intestinal microbiota and human health [1–3], attention has focused on products that can beneficially manipulate the microbiota profile. Probiotics are commonly defined as live microorganisms, which when administered in adequate amounts confer a health benefit on the host . To date, a large number of studies have been conducted to assess the potential beneficial effect of probiotics in the treatment and prevention of pediatric disease, including acute gastroenteritis, antibiotic associated diarrhea, necrotizing enterocolitis (NEC), constipation, allergic disease, colic and respiratory infections . A recent review of the evidence by the Canadian Paediatric Society states that physicians should consider the use of probiotics in infants for the prevention of antibiotic-associated diarrhea, treatment of acute diarrhea, in the prevention of NEC in preterm infants and to decrease symptoms of colic and irritable bowel syndrome . In contrast, other reviews have concluded that while a number of randomized controlled trials demonstrate encouraging results, clear clinical benefits of probiotics for prevention of disease in infants is not yet convincing [5, 7, 8].
Efficacy of probiotics depends on the species and strain of bacteria, as well as the dosage and length of administration. Heterogeneity in these variables among studies as well as inadequacies in study design has likely contributed to the conflicting outcomes in probiotic studies to date, hampering their translation into evidence-based recommendations [9, 10]. In addition, several concerns exist regarding the use of probiotics in infants due to their immature gastrointestinal and immune systems. Although extremely rare, probiotic bacteria have the potential to translocate through the gut epithelium and cause bacteraemia or sepsis . The long term effect of administration of bacterial strains during the early development of the gut microbiota is also unknown. A recent study evaluating the safety of probiotics used in young children aged 0 – 2 years found no major safety concerns but highlighted that inconsistent and incomplete reporting of adverse events in studies and variation of strains and dosage used limit the generalizability of conclusions . Overall, although predominantly deemed safe for use in healthy term infants, there is a consensus that more strain-specific safety data in this population group is needed, as well as evidence on longer term effects [5, 8, 12, 13].
In many countries, probiotics are categorized as foods or dietary supplements rather than medicines and therefore can be readily purchased in grocery and health food stores without a prescription or professional advice. There is growing availability of probiotic products marketed for infants and young children which include yogurts, liquid supplements and weaning foods. Probiotics are also now included in a number of infant formulae worldwide as evidence of the presence of live bacteria in breast milk increases .
Given the recent scientific attention, coupled with the increasing availability of probiotic products, it is important that practitioners have an understanding of patient knowledge and opinions surrounding probiotics, as well as their current use in infants to enable effective translation of research knowledge as it becomes available. The aim of this cross-sectional survey of mothers was to ascertain extent of probiotic use in infants, and maternal knowledge and opinions on their safety and effectiveness.
Mothers were recruited via email from the Alberta Pregnancy Outcomes and Nutrition (APrON) cohort study. APrON is an ongoing prospective general birth cohort of pregnant women and their infants from Calgary and Edmonton, Alberta (Western Canada) . In Calgary, women were enrolled in APrON primarily through prenatal clinics, although community advertising and media coverage were also used. Due to differences in obstetrical care between the cities, women in Edmonton were recruited primarily through local media coverage, paid advertising and recruitment tables at shopping malls, recreational centres and community fairs. An APrON webpage was also used to recruit participants in both cities. After women expressed interest in the study, APrON research assistants contacted prospective participants to describe the study in more detail. Pregnant women over the age of 16 years with a gestation <27 weeks, and living in or near Calgary or Edmonton were eligible. Women were excluded if they were unable to answer questions in English or if they planned to move out of the region during the timeframe of the study. Mothers in APrON are self-reported to be primary caregivers of their infants. For the current survey, mothers were eligible for inclusion if they had a child aged two years or younger enrolled in APrON at the time of the survey administration and had given consent to be contacted about other studies outside of APrON.
The self-administered web-based survey consisted of 29 questions in themed sections. We report here on responses to 9 questions relating to maternal awareness of probiotics, use in self and infants, as well as opinions surrounding probiotic use in infants. Standard demographic information was also captured as part of the survey. The survey was constructed and validated by six researchers in child health with expertise in microbiota research, nutrition, psychology, ethics and questionnaire design. It was subsequently piloted on 5 pregnant women or new mothers to verify understanding; pilot testing resulted in minor changes to the wording of some questions. The survey was conducted using Checkbox® v4.7, hosted on a secure server at the University of Alberta and was completed anonymously. Mothers who completed the survey were entered into a lottery prize draw to win a gift card. An email reminder was sent approximately 3 weeks after the initial invitation to encourage participation.
The research protocol and all study materials and incentives were approved by the Health Research Ethics Board of the University of Alberta and the Cojoint Health Research Ethics Board at the University of Calgary. Consent was obtained from all participants before completion of the survey.
Frequencies were compiled for all variables. Chi-square analysis was used to determine the association between use of probiotics in infants, sociodemographic characteristics and maternal opinions of probiotic benefit and safety. Mean differences in maternal opinion on safety across groups of commonly used products in infancy, including probiotics, was tested using the non-parametric version of repeated-measures analysis of variance (Friedman Test) with post hoc Wilcoxon signed-rank tests to further explore differences in perceived safety between probiotics specifically and all other food/products. The Wilcoxon signed rank test was used to explore differences in the intended use of probiotics based on a number of hypothetical scenarios of health effects compared to intention to use if no health effects were demonstrated. Responses to open questions were hand coded into relevant themes to enable reporting of frequencies. Statistical analysis was performed using IBM SPSS Statistics for Windows version 21.0
During April 2012, 1327 women who had enrolled in the APrON cohort study between September 2009 and December 2011 were invited by email to participate in the survey. Of the 1327 contacted, 426 subjects followed the link to the survey consent and information page. In the final analysis, 13 subjects were excluded (two did not give consent; 11 gave consent but did not complete any of the questions). In total, 413 mothers completed the survey after giving consent, representing a response rate of 31%.
Characteristics of survey participants
Age range (N = 388)
Marital Status (N = 389)
Common-law/Living with partner
Highest Level of Education (N = 389)
Less than high school
Household Income (N = 382)
$100,000 or more
Children (under 18 yrs) in the Household ( N = 389 mean ± SD)
Age of youngest child in months (N = 388 mean ± SD)
Ethnic origin (N = 383)
First Nations/ Metis
Birth place (N = 388)
Use of probiotic products
Use of probiotics by mothers and infants and reason for usage
Use of probiotics (N = 413)
Reason for usage (N = 413)a:
I read/heard about probiotics on TV/internet/newspaper/magazine
Recommendation from friend/relative
Recommendation from physician/pharmacist
Recommendation from naturopath
Recommendation from midwife
Recommendation from lactation consultant
Probiotics have helped me in the past
Half of mothers reported giving a probiotic product to their infant (50.8%). The main reasons indicated for doing so included information from the media, recommendation from a healthcare professional and/or recommendation from a friend or relative (Table 2). Maternal use of probiotics was found to be positively associated with their use in infants (Pearson Chi-Square test P < 0.001; OR 3.99 95%CI:1.75-9.14). There were no significant differences in demographic characteristics (age, marital status, education, income, ethnic origin or birth place) between mothers that reported giving probiotic products to their infants and those that did not.
Awareness and understanding of probiotics
Awareness of probiotics was high, with 99.3% of mothers reporting that they had heard of the term.
Mothers were subsequently asked to provide their own definition of probiotics (“Please describe what you think probiotics are”). The majority (73.6%) of the 402 respondents who answered this question correctly indicated that probiotics were or contained bacteria, microbes, microorganisms or they used other similar terminology. Only a minority of mothers (4.2%) wrongly described them as other entities such as enzymes, proteins, plant extracts, nuts, herbal supplements or vitamins/minerals.
Below are a selection of typical responses to the question, “Please describe what you think probiotics are.”:
“Probiotics are micro-organisms found in things like yogurt. They are beneficial and aid in digestion.”
“Healthy bacteria for the gut”
“Good bacteria that help with the normal functioning of the digestive system”
“Bacteria, the good ones”
“Product that helps the healthy bacteria in your intestines”
Maternal beliefs of probiotics
Please indicate your agreement with the following statements N = 407(%)
Probiotics contain live bacteria
Probiotics can alter a person’s microbiota (the bacteria in a person’s digestive system)
The benefit/effectiveness of using probiotics in infants has been confirmed by scientific research
Benefit and safety of probiotics
Comparison of maternal perception of safety of probiotics and other foods/products for use in infants
Frequency (1 = most safe; 5 = least safe) (%)
Organic leafy green vegetables
Intent to use probiotics based on hypothetical health effects
Maternal intent to use probiotics based on hypothetical research outcomes
Likelihood to use probiotics %
If you had another child, please indicate how likely you would be to give them probiotics if research showed that:
Giving babies probiotics has no benefit to their health (N = 391)
Giving babies probiotics reduces their chances of getting a disease (N = 392)
The health benefits of giving probiotics to babies is uncertain but may have harmful effects (N = 391)
Giving probiotics to babies permanently changes their microbiota (i.e. bacteria living in their digestive system) (N = 391)
This cross-sectional study of 413 mothers in Alberta, Canada indicates that awareness of probiotics is high, with close to 90% of mothers reporting use of these products. Despite knowing they contain live bacteria, mothers’ attitudes towards probiotics in general were positive and did not elicit any negative or harmful connotations. Many mothers indicated that they had used probiotics themselves and these mothers were four times more likely to have given probiotic products to their infants.
To date, research on attitudes towards probiotics has been limited to studies in adult populations with gastrointestinal problems [16, 17], studies of complementary and alternative medicine use in children  and most recently parental perspectives on the use of probiotics in preterm infants . In a cross-sectional study of children attending gastroenterology clinics in Australia, probiotics were used by 50% of children, second only to nutritional supplements (56%) . We report here our finding of similar high usage in our population (51%) of healthy infants and young children.
Since the body of research on the beneficial health effects of probiotics in young children continues to grow, characterizing mothers’ knowledge and opinions on the use of probiotic products is important. Our study showed that mothers rank probiotics as “safer” for infants than other commonly used products such as vitamins, herbal remedies and antibiotics, suggesting that mothers see probiotics as relatively low-risk. The finding is comparable to research on patients with gastrointestinal disorders who similarly viewed probiotics as a more natural and low-risk therapeutic option compared to pharmaceutical treatments . It has been argued that the marketing of probiotics and their widespread availability at grocery stores reinforces this perception among consumers . However, the relatively low use in infants compared to mothers’ usage (51 vs 89%), and maternal uncertainty over their safe use in infants suggests that mothers are more cautious about their use in this population group or unsure of the benefits to their infant. Indeed, many mothers stated that they were uncertain whether probiotic use in infants has been proven to be beneficial by scientific research. Many also indicated that they didn’t have enough information to describe their views of probiotics or safety for use in infants. This result is unsurprising given that current research on benefits of probiotics in prevention and treatment of pediatric disorders is conflicting and in many cases not yet convincing enough to warrant healthcare recommendations.
An interesting finding from our study was that whilst the majority of mothers acknowledged that probiotics can alter a person’s microbiota, when presented with the hypothetical scenario that probiotics could permanently alter their infant’s microbiota, the majority would choose not to use them. While a permanent change could be “permanently beneficial”, this scenario was clearly perceived as negative by mothers in the current survey. In reality, research in both adults and older children suggests that probiotic use only transiently alters gut microbiota profiles ; however, it is plausible that exposure to probiotics in infancy during this dynamic phase of intestinal microbiota development could cause more persistent changes. Indeed, there is evidence that other types of early life exposures capable of disrupting the normal development of the microbiota, such as antibiotic use and cesarean section delivery, can have a long lasting impact on the gut microbiota of infants [22–25]. Although our present study was not designed to explore this further, it will be important for other studies to investigate the underlying reasons for these views due to their potential to limit mothers’ uptake if therapeutic use of probiotics becomes more common in the future.
There are a number of limitations inherent to self-administered web-based survey designs that must be considered when interpreting the results. The most important consideration is the introduction of bias due to non-response. Our response rate of 31%, although typical of self-administered survey designs , is low and it is possible that survey respondents differ substantially from those that did not respond. For example, individuals already aware of, or using, probiotics may be more likely to respond to the survey, thus biasing results regarding usage and knowledge. We were mindful of the potential for non-response bias and took a number of steps in the design and administration of the survey to maximize response rates that have been shown to be effective in other studies [26–28], including official sponsorship and use of a trusted email contact, non-monetary incentives and reminders. Analysis of demographic characteristics of respondents revealed that they were similar in all respects to the total APrON cohort, except for level of education. This fact, coupled with the tendency of the general APrON cohort to over represent older, more educated mothers, may limit the generalizability of our findings to the wider Canadian population. Further, we were unable to survey fathers, who may have different perspectives. Given fathers’ increasing roles in child care , fathers’ perspectives need to be taken into account by health practitioners. Finally, whilst the present study provides an initial overview of mothers’ perspectives of probiotic use in infants, the design did not allow for detailed investigation surrounding attitudes. Future qualitative studies using in-depth interview techniques on a broader spectrum of the population will be important to develop greater understanding of parental use of probiotics in infants and to investigate factors important for effective knowledge translation.
The present cross-sectional study indicates that awareness and understanding of probiotics are high among a relatively well educated group of mothers in Alberta, Canada. Over half of mothers had given probiotic products to their infants. However, for some mothers, there is still uncertainty regarding the benefit of probiotics and their safety in infants. Further studies on the benefits and safety of probiotic use in healthy infants as well as investment in the translation of research findings to parents are warranted to address these concerns.
This research was funded by the Canadian Institutes of Health Research. APrON was funded by Alberta Innovates – Health Solutions. We thank Pam Marples for informatics assistance with the web survey administration, James Anderson and MSc student Alicia Pawlowski in assisting in the survey design, Krista Gray for her involvement in coordinating the survey administration and Andrea Deane and Anne Gilbert from APrON study team for administering the survey. We also wish to extend our sincere appreciation to the APrON study families and research team for their support and participation in this research. The individual members of the APrON research team are Nicole Letourneau, Catherine J. Field, Deborah Dewey, Rhonda C. Bell, Francois P. Bernier, Marja Cantell, Linda M. Casey, Misha Eliasziw, Anna Farmer, Lisa Gagnon, Gerald F. Giesbrecht, Laki Goonewardene, David W. Johnston, Bonnie J. Kaplan, Libbe Kooistra, Brenda MY Leung, Donna P. Manca, Jonathan W. Martin, Linda J. McCargar, Maeve O’Beirne, Victor J. Pop, Nalini Singhal. At the time of the research MBA held a Banting Postdoctoral Fellowship and was supported by Alberta Innovates - Health Solutions. ALK held a Research Chair supported by the Women and Children's Health Research Institute/Stollery Children's Hospital Foundation.
- Sommer F, Backhed F: The gut microbiota–masters of host development and physiology. Nat Rev Microbiol. 2013, 11: 227-238. 10.1038/nrmicro2974.View ArticlePubMedGoogle Scholar
- Nicholson JK, Holmes E, Kinross J, Burcelin R, Gibson G, Jia W, Pettersson S: Host-gut microbiota metabolic interactions. Science. 2012, 336: 1262-1267. 10.1126/science.1223813.View ArticlePubMedGoogle Scholar
- Tremaroli V, Backhed F: Functional interactions between the gut microbiota and host metabolism. Nature. 2012, 489: 242-249. 10.1038/nature11552.View ArticlePubMedGoogle Scholar
- Food and Agriculture Organization of the United Nations (FAO): Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. 2001, Argentina: Food and Agriculture Organization of the United Nations (FAO)Google Scholar
- Vandenplas Y, De Greef E, Devreker T, Veereman-Wauters G, Hauser B: Probiotics and prebiotics in infants and children. Curr Infect Dis Rep. 2013, 15: 251-262. 10.1007/s11908-013-0334-4.View ArticlePubMedGoogle Scholar
- Marchand V: Using probiotics in the paediatric population. Paediatr Child Health. 2012, 17: 575-576.PubMedPubMed CentralGoogle Scholar
- Azad MB, Coneys JG, Kozyrskyj AL, Field CJ, Ramsey CD, Becker AB, Friesen C, Abou-Setta AM, Zarychanski R: Probiotic supplementation during pregnancy or infancy for the prevention of asthma and wheeze: systematic review and meta-analysis. BMJ. 2013, 347: 6471-10.1136/bmj.f6471.View ArticleGoogle Scholar
- Thomas DW, Greer FR: Probiotics and prebiotics in pediatrics. Pediatrics. 2010, 126: 1217-1231. 10.1542/peds.2010-2548.View ArticlePubMedGoogle Scholar
- Weichert S, Schroten H, Adam R: The role of prebiotics and probiotics in prevention and treatment of childhood infectious diseases. Pediatr Infect Dis J. 2012, 31: 859-862.View ArticlePubMedGoogle Scholar
- Sanders ME, Guarner F, Guerrant R, Holt PR, Quigley EM, Sartor RB, Sherman PM, Mayer EA: An update on the use and investigation of probiotics in health and disease. Gut. 2013, 62: 787-796. 10.1136/gutjnl-2012-302504.View ArticlePubMedPubMed CentralGoogle Scholar
- Boyle RJ, Robins-Browne RM, Tang ML: Probiotic use in clinical practice: what are the risks?. Am J Clin Nutr. 2006, 83: 1256-1264.PubMedGoogle Scholar
- van den Nieuwboer M, Claassen E, Morelli L, Guarner F, Brummer RJ: Probiotic and synbiotic safety in infants under two years of age. Benef Microbes. 2014, 5: 45-60. 10.3920/BM2013.0046.View ArticlePubMedGoogle Scholar
- Braegger C, Chmielewska A, Decsi T, Kolacek S, Mihatsch W, Moreno L, Piescik M, Puntis J, Shamir R, Szajewska H, Turck D, van Goudoever J: Supplementation of infant formula with probiotics and/or prebiotics: a systematic review and comment by the ESPGHAN committee on nutrition. J Pediatr Gastroenterol Nutr. 2011, 52: 238-250. 10.1097/MPG.0b013e3181fb9e80.View ArticlePubMedGoogle Scholar
- Jeurink PV, van Bergenhenegouwen J, Jimenez E, Knippels LM, Fernandez L, Garssen J, Knol J, Rodriguez JM, Martin R: Human milk: a source of more life than we imagine. Benef Microbes. 2013, 4: 17-30. 10.3920/BM2012.0040.View ArticlePubMedGoogle Scholar
- Kaplan BJ, Giesbrecht GF, Leung BM, Field CJ, Dewey D, Bell RC, Manca DP, O’Beirne M, Johnston DW, Pop VJ, Singhal N, Gagnon L, Bernier FP, Eliasziw M, McCargar LJ, Kooistra L, Farmer A, Cantell M, Goonewardene L, Casey LM, Letourneau N, Martin JW: The Alberta Pregnancy Outcomes and Nutrition (APrON) cohort study: rationale and methods. Matern Child Nutr. 2014, 10: 44-60. 10.1111/j.1740-8709.2012.00433.x.View ArticlePubMedGoogle Scholar
- Harrison KL, Farrell RM, Brinich MA, Highland J, Mercer M, McCormick JB, Tilburt J, Geller G, Marshall P, Sharp RR: ‘Someone should oversee it’: patient perspectives on the ethical issues arising with the regulation of probiotics. Health Expect. 2012, in pressGoogle Scholar
- Mercer M, Brinich MA, Geller G, Harrison K, Highland J, James K, Marshall P, McCormick JB, Tilburt J, Achkar JP, Farrell RM, Sharp RR: How patients view probiotics: findings from a multicenter study of patients with inflammatory bowel disease and irritable bowel syndrome. J Clin Gastroenterol. 2012, 46: 138-144. 10.1097/MCG.0b013e318225f545.View ArticlePubMedPubMed CentralGoogle Scholar
- Wadhera V, Lemberg DA, Leach ST, Day AS: Complementary and alternative medicine in children attending gastroenterology clinics: usage patterns and reasons for use. J Paediatr Child Health. 2011, 47: 904-910. 10.1111/j.1440-1754.2011.02100.x.View ArticlePubMedGoogle Scholar
- Sesham R, Oddie S, Embleton ND, Clarke P: Probiotics for preterm neonates: parents’ perspectives and present prevalence. Arch Dis Child Fetal Neonatal Ed. 2014, doi:10.1136/archdischild-2014-306344. [Epub ahead of print]Google Scholar
- Sharp RR, Achkar JP, Brinich MA, Farrell RM: Helping patients make informed choices about probiotics: a need for research. Am J Gastroenterol. 2009, 104: 809-813. 10.1038/ajg.2008.68.View ArticlePubMedPubMed CentralGoogle Scholar
- Gerritsen J, Smidt H, Rijkers GT, de Vos WM: Intestinal microbiota in human health and disease: the impact of probiotics. Genes Nutr. 2011, 6: 209-240. 10.1007/s12263-011-0229-7.View ArticlePubMedPubMed CentralGoogle Scholar
- Fouhy F, Guinane CM, Hussey S, Wall R, Ryan CA, Dempsey EM, Murphy B, Ross RP, Fitzgerald GF, Stanton C, Cotter PD: High-throughput sequencing reveals the incomplete, short-term recovery of infant gut microbiota following parenteral antibiotic treatment with ampicillin and gentamicin. Antimicrob Agents Chemother. 2012, 56: 5811-5820. 10.1128/AAC.00789-12.View ArticlePubMedPubMed CentralGoogle Scholar
- Azad MB, Konya T, Maughan H, Guttman DS, Field CJ, Chari RS, Sears MR, Becker AB, Scott JA, Kozyrskyj AL: Gut microbiota of healthy Canadian infants: profiles by mode of delivery and infant diet at 4 months. CMAJ. 2013, 185: 385-394. 10.1503/cmaj.121189.View ArticlePubMedPubMed CentralGoogle Scholar
- Salminen S, Gibson GR, McCartney AL, Isolauri E: Influence of mode of delivery on gut microbiota composition in seven year old children. Gut. 2004, 53: 1388-1389.View ArticlePubMedPubMed CentralGoogle Scholar
- Gronlund MM, Lehtonen OP, Eerola E, Kero P: Fecal microflora in healthy infants born by different methods of delivery: permanent changes in intestinal flora after cesarean delivery. J Pediatr Gastroenterol Nutr. 1999, 28: 19-25. 10.1097/00005176-199901000-00007.View ArticlePubMedGoogle Scholar
- Cook C, Health F, Thompson RL: A meta-analysis of response rates in web- or internet-based surveys. Educ Psychol Meas. 2000, 60: 821-836. 10.1177/00131640021970934.View ArticleGoogle Scholar
- Sanchez-Fernandez J, Munoz-Leiva F, Montoro-Rios FJ: Improving retention rate and response quality in Web-based surveys. Comput Hum Behav. 2012, 28: 507-514. 10.1016/j.chb.2011.10.023.View ArticleGoogle Scholar
- Fan WM, Yan Z: Factors affecting response rates of the web survey: A systematic review. Comput Hum Behav. 2010, 26: 132-139. 10.1016/j.chb.2009.10.015.View ArticleGoogle Scholar
- Seward R, Stanley-Stevens L: Fathers, fathering, and fatherhood across cultures. Parenting Across Cultures. Edited by: Selin HNY. 2014, Dordrecht: Springer, 459-474.View ArticleGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6882/14/366/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.